New drug targets tough tumors in early trial
NCT ID NCT07622524
First seen Jun 07, 2026 · Last updated Jun 13, 2026 · Updated 1 time
Summary
This early-stage study tests a new drug called CS5007 in people with advanced solid tumors that have not responded to other treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to find a safe dose and see if the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icon Cancer Centre South Brisbane
South Brisbane, Queensland, 4101, Australia
Contact
-
Linear Clinical Research
Nedlands, Western Australia, 6009, Australia
Contact
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 200030, China
Contact
Contact
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.